The study aimed to investigate whether the mechanism underlying DTX’s anti-GN effects involves TLR4/MyD88/NF-κB pathway modulation, thereby diminishing inflammatory factor release and ultimately enhancing kidney protection. This evidence concerns the gene MYD88 and ganglioneuroma.